-
公开(公告)号：US20240308979A1
公开(公告)日：2024-09-19
申请号：US18483436
申请日：2023-10-09
申请人： Novartis AG
IPC分类号： C07D401/14 , A61K31/497 , A61K31/506 , A61K45/06 , A61P31/04 , A61P35/00 , C07D413/14
CPC分类号： C07D401/14 , A61K31/497 , A61K31/506 , A61K45/06 , A61P31/04 , A61P35/00 , C07D413/14
摘要： PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
-
公开(公告)号：US11059804B2
公开(公告)日：2021-07-13
申请号：US16666108
申请日：2019-10-28
申请人： Novartis AG
IPC分类号： A61K31/497 , C07D401/14 , C07D413/14 , A61P31/04 , A61K31/506 , A61P35/00 , A61K45/06
摘要： PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
-
公开(公告)号：US11845730B2
公开(公告)日：2023-12-19
申请号：US17656313
申请日：2022-03-24
申请人： Novartis AG
发明人： Donglei Liu , Julien Papillon , Stefan Peukert , James J. Powers
IPC分类号： C07D217/02 , C07D401/12 , C07D405/12 , C07D417/12
CPC分类号： C07D217/02 , C07D401/12 , C07D405/12 , C07D417/12
摘要： Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition described herein.
-
公开(公告)号：US20200262814A1
公开(公告)日：2020-08-20
申请号：US16666108
申请日：2019-10-28
申请人： Novartis AG
IPC分类号： C07D401/14 , A61K45/06 , A61P35/00 , A61K31/506 , A61P31/04 , C07D413/14 , A61K31/497
摘要： PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
-
公开(公告)号：US20240270738A1
公开(公告)日：2024-08-15
申请号：US18602126
申请日：2024-03-12
申请人： NOVARTIS AG
发明人： Christopher ADAIR , Katsumasa Nakajima , Rukundo Ntaganda , Julien Papillon , Troy Douglas Smith
IPC分类号： C07D417/12 , A61K45/06
CPC分类号： C07D417/12 , A61K45/06
摘要： A method of preparing compound of Formula (1), or a pharmaceutically acceptable salt thereof,
wherein R1 through R6 are as defined herein.-
公开(公告)号：US11505541B2
公开(公告)日：2022-11-22
申请号：US17200509
申请日：2021-03-12
申请人： Novartis AG
IPC分类号： A61K31/497 , C07D401/14 , C07D413/14 , A61P31/04 , A61K31/506 , A61P35/00 , A61K45/06
摘要： PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
-
公开(公告)号：US11958846B2
公开(公告)日：2024-04-16
申请号：US17268512
申请日：2019-08-12
申请人： Novartis AG
发明人： Christopher Adair , Katsumasa Nakajima , Rukundo Ntaganda , Julien Papillon , Troy Douglas Smith
IPC分类号： C07D417/12 , A61K45/06
CPC分类号： C07D417/12 , A61K45/06
摘要： A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a BRM-mediated and/or BRG1-mediated disease or disorder: Formula (I) wherein R1 through R6 are as defined herein.
-
公开(公告)号：US10508101B2
公开(公告)日：2019-12-17
申请号：US16354416
申请日：2019-03-15
申请人： Novartis AG
IPC分类号： A61K31/497 , C07D401/14 , C07D413/14 , A61P31/04 , A61K31/506 , A61P35/00 , A61K45/06
摘要： PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
-
公开(公告)号：US20210387962A1
公开(公告)日：2021-12-16
申请号：US17200509
申请日：2021-03-12
申请人： Novartis AG
IPC分类号： C07D401/14 , A61K31/497 , C07D413/14 , A61P31/04 , A61K31/506 , A61P35/00 , A61K45/06
摘要： PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
-
公开(公告)号：US20190202809A1
公开(公告)日：2019-07-04
申请号：US16354416
申请日：2019-03-15
申请人： Novartis AG
IPC分类号： C07D401/14 , C07D413/14 , A61P35/00 , A61K31/497 , A61P31/04 , A61K31/506
摘要： PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.017 秒)
